WEBULL
News
INO
1.580
-1.86%
-0.030
Piper Sandler Reaffirms Their Buy Rating on Inovio Pharmaceuticals (INO)
TipRanks · 3d ago
Inovio Pharmaceuticals Inc. Stock Slides 5.9%, Underperforms Peers
Dow Jones · 3d ago
Weekly Report: what happened at INO last week (1229-0102)?
Weekly Report · 4d ago
Looking Into Inovio Pharmaceuticals Inc's Recent Short Interest
Benzinga · 01/02 14:00
Inovio Pharmaceuticals Inc. Stock Rallies 1.7%, Outperforms Peers
Dow Jones · 12/30/2025 21:35
Inovio Pharmaceuticals Inc. Stock Slides 24.5%, Underperforms Peers
Dow Jones · 12/29/2025 21:32
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga · 12/29/2025 17:33
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 12/29/2025 17:05
Inovio Stock Sinks As FDA Pushes Back On Accelerated Approval For Rare Disease Drug
Benzinga · 12/29/2025 16:59
Balanced View on INOVIO’s INO-3107: Strong Long-Term Data Offset by Regulatory and Timing Uncertainty Driving Hold Rating
TipRanks · 12/29/2025 16:45
Inovio drops as respiratory papillomatosis asset denied accelerated review
Seeking Alpha · 12/29/2025 15:42
Inovio Shares Drop After FDA Says No Plans to Discuss INO-3107 Application
Dow Jones · 12/29/2025 15:39
FDA Accepts Inovio’s BLA for INO-3107 Review
TipRanks · 12/29/2025 13:47
Inovio announces U.S. FDA accepted BLA for INO-3107
TipRanks · 12/29/2025 13:10
FDA Accepts Inovio's BLA for INO-3107 to Treat Recurrent Respiratory Papillomatosis
Reuters · 12/29/2025 13:05
INOVIO PHARMACEUTICALS INC: NOT CURRENTLY PLANNING TO SEEK APPROVAL FOR INO-3107 UNDER TRADITIONAL PATHWAY
Reuters · 12/29/2025 13:05
Weekly Report: what happened at INO last week (1222-1226)?
Weekly Report · 12/29/2025 09:50
Inovio Pharmaceuticals Inc. Stock Advances 1.8%, Outperforms Peers
Dow Jones · 12/26/2025 21:34
Inovio Pharmaceuticals Inc. Stock Rises 4.7%, Outperforms Peers
Dow Jones · 12/24/2025 21:32
Inovio Pharmaceuticals Inc. Stock Sheds 4.4%, Underperforms Peers
Dow Jones · 12/23/2025 21:33
More
Webull provides a variety of real-time INO stock news. You can receive the latest news about Inovio Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.